Absorption of colesevelam hydrochloride in healthy volunteers

被引:31
作者
Heller, DP
Burke, SK
Davidson, DM
Donovan, JM
机构
[1] Pharmaceut Profiles Inc, Business Dev, Princeton, NJ 08540 USA
[2] GelTex Pharmaceut, Clin Res, Waltham, MA USA
关键词
absorption; colesevelam; sequestrant;
D O I
10.1345/aph.1A143
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To assess whether colesevelam hydrochloride is absorbed in healthy volunteers. METHODS: A single-center, open-label, radiolabeled study was performed with 16 healthy volunteers. Subjects were administered non-radiolabeled colesevelam hydrochloride 1.9 g twice daily for 4 weeks, followed by a single dose of [C-14] -colesevelam 2.4 g (480 muCi). These subjects continued to receive non-radioactive colesevelam 1.9 g twice daily for 4 days after administration of the radiolabeled dose. Blood, urine, and feces were collected immediately prior to administration of [C-14]-colesevelam and at specified intervals after administration. The whole-blood equivalent concentration of colesevelam was calculated using data collected throughout the 96 hours following radiolabeled drug administration. The proportion of [C-14]-colesevelam excreted through urine or feces was calculated based on the amount of radioactivity recovered up to 216 hours after the radiolabeled dose. RESULTS: The mean cumulative total recovery of [C-14]-colesevelam in urine and feces was 0,05% and 74%, respectively. Excluding 2 subjects for whom cumulative recovery was <25%, the mean cumulative fecal recovery was 82%. The mean maximum whole-blood equivalent concentration of colesevelam was 0.165 +/- 0.10 mug equiv/g 72 hours after administration of [C-14]-colesevelam, which was estimated to be 0.04% of the administered dose. All blood samples contained <4 times the number of background counts (dpm). CONCLUSIONS: The cumulative recovery data in urine and feces are consistent with the conclusion that colesevelam is not absorbed and is excreted entirely through the gastrointestinal system.
引用
收藏
页码:398 / 403
页数:6
相关论文
共 47 条
[1]  
[Anonymous], 1992, ARCH INTERN MED, V152, P1399
[2]  
[Anonymous], 2000, POLYM PREPRINTS
[3]  
Assmann G, 1998, EUR HEART J, V19, pA2
[4]   A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
SCIENCE, 1986, 232 (4746) :34-47
[5]  
Campeau L, 1997, NEW ENGL J MED, V336, P153
[6]   INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY [J].
CASTELLI, WP ;
GARRISON, RJ ;
WILSON, PWF ;
ABBOTT, RD ;
KALOUSDIAN, S ;
KANNEL, WB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20) :2835-2838
[7]   SERUM-CHOLESTEROL CONCENTRATION AND CORONARY HEART-DISEASE IN POPULATION WITH LOW CHOLESTEROL CONCENTRATIONS [J].
CHEN, ZM ;
PETO, R ;
COLLINS, R ;
MACMAHON, S ;
LU, JR ;
LI, WX .
BRITISH MEDICAL JOURNAL, 1991, 303 (6797) :276-282
[8]  
CHENG HY, 1994, DRUG METAB DISPOS, V22, P139
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   Role of the enterohepatic circulation of bile salts in lipoprotein metabolism [J].
Cooper, AD .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (01) :211-+